Dr. Poldrack's lab uses the tools of cognitive neuroscience to understand how decision making, executive control, and learning and memory are implemented in the human brain.

Dr. Wu spearheads the oculoplastic research program at Stanford University and is developing cutting edge stem cell and regenerative medicine treatments for vision loss and other eye diseases.

Dr. Leng has an active program in imaging informatics and deep learning to perform big data analyses of retinal scans to identify patients who are at risk for retinal disease deterioration, with the end goal of earlier detection and rapid treatment to maximize visual outcomes; and is considered a leading expert optical coherence tomography (OCT), a non-invasive and non-contact imaging technique for the retina.

Dr. Fischbach's laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome.

The Myung Research Group is a translational laboratory focused on two areas of clinical need: ophthalmic regenerative medicine through tissue engineering and drug delivery; and global health through mobile technologies and telemedicine.

The Zuchero Lab aims to uncover how glial cells regulate neural development and how their dysfunction contributes to diseases like multiple sclerosis (MS) and in injuries like stroke.

Dr. Chiu's research is the development of methodology for electron cryo-microscopy to determine 3D structures of macromolecules, molecular machines, organelles and cells.

Dr. Jagannathan is an Infectious Diseases specialist with 7 years of experience in translational immunology research focused on pathogen-specific cellular immune responses.

Dr. Beadle's research goals are to improve the outcomes of patients diagnosed with head and neck cancer through the integration of novel agents with radiation therapy, understanding key molecular drivers of the disease, and optimizing the use of advanced computational and physics-based approaches to improve treatment planning.

Dr. Moss's aim is to develop non-invasive structural and functional markers of papilledema physiology that predict visual outcomes in idiopathic intracranial hypertension (IIH) and guide tailored intervention that will improve visual outcomes and prevent blindness.